Moody Lynn & Lieberson LLC Purchases 8,500 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Moody Lynn & Lieberson LLC grew its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 63.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 22,000 shares of the biotechnology company’s stock after purchasing an additional 8,500 shares during the quarter. Moody Lynn & Lieberson LLC’s holdings in Arrowhead Pharmaceuticals were worth $1,461,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in ARWR. iSAM Funds UK Ltd bought a new stake in Arrowhead Pharmaceuticals during the 3rd quarter valued at approximately $29,000. Salomon & Ludwin LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the third quarter worth approximately $34,000. Federated Hermes Inc. bought a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at approximately $52,000. Smartleaf Asset Management LLC boosted its position in shares of Arrowhead Pharmaceuticals by 2,186.5% in the third quarter. Smartleaf Asset Management LLC now owns 1,692 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 1,618 shares during the period. Finally, Virtus Advisers LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the second quarter worth $34,000. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Stock Up 8.8%

ARWR opened at $62.70 on Wednesday. The company has a market capitalization of $8.78 billion, a P/E ratio of 40.98 and a beta of 1.23. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.38 and a quick ratio of 3.38. The firm’s fifty day moving average price is $62.69 and its two-hundred day moving average price is $54.23. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $9.57 and a fifty-two week high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The business had revenue of $264.03 million during the quarter, compared to analyst estimates of $225.66 million. During the same quarter in the prior year, the company posted ($1.39) EPS. The company’s quarterly revenue was up 10461.3% compared to the same quarter last year. On average, analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insider Buying and Selling

In other news, insider James C. Hamilton sold 40,164 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $63.11, for a total value of $2,534,750.04. Following the sale, the insider directly owned 171,958 shares in the company, valued at approximately $10,852,269.38. This represents a 18.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Patrick O’brien sold 49,493 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $63.11, for a total value of $3,123,503.23. Following the completion of the transaction, the chief operating officer directly owned 474,908 shares of the company’s stock, valued at approximately $29,971,443.88. The trade was a 9.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 112,844 shares of company stock valued at $7,171,814 over the last quarter. Corporate insiders own 3.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, March 25th. Chardan Capital raised their price target on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Morgan Stanley upped their price objective on shares of Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 7th. The Goldman Sachs Group increased their target price on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, January 7th. Finally, Weiss Ratings raised Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Arrowhead Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $81.67.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.